An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

E-ISSN： 1757-4684|10|2|294-308

ISSN： 1757-4676

Source： EMBO Molecular Medicine, Vol.10, Iss.2, 2018-02, pp. : 294-308

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Detection and monitoring of driver mutations by next‐generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR‐tyrosine kinase inhibitors

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 181-184

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of therapeutic effects of EGFR‐tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function

Thoracic Cancer, Vol. 9, Iss. 2, 2018-02 ,pp. : 228-233

John Wiley & Sons Inc

Access to resources Recommend Favorite

London Borough of Lewisham launches management competencies and pilots third-generation development centres

Competency & Emotional Intelligence Quarterly, Vol. 8, Iss. 3, 2001-04 ,pp. : 9-11

Industrial Relations Services

Access to resources Recommend Favorite

MiR‐5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6

Molecular Carcinogenesis, Vol. 57, Iss. 3, 2018-03 ,pp. : 419-428

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role of acetylcholinesterase in lung cancer

Thoracic Cancer, Vol. 6, Iss. 4, 2015-07 ,pp. : 390-398

John Wiley & Sons Inc

Access to resources Recommend Favorite